Lumos Diagnostics (ASX:LDX) share price climbs amid RAT mania

Lumos share price rises amid RAT test drama

| More on:
a group of doctors and medical staff in uniform high five in celebration in a hospital setting

Image source: Getty Images

Key points

  • The Lumos Diagnostics share price is rising today
  • COVID-19 rapid antigen tests are in focus this week
  • The company’s CoviDX RAT test is waiting on TGA approval

The Lumos Diagnostics Holdings Ltd (ASX: LDX) share price is rising today as COVID-19 rapid antigen tests (RATS) hit the headlines.

At the time of writing, the company’s share price is trading hands at 1.01, up 1.5%.

Let’s take a look at what might be impacting the company’s share price.

Awaiting TGA approval

The Lumos Diagnostics share price has been skyrocketing in recent weeks as demand for COVID-19 RAT tests increases globally.

Since Christmas Eve, the company’s shares have gained 44%, rising from 70 cents to the current share price. Lumos Diagnostics achieved record revenue of $22.7 million in the 2021 financial year, up 188% from FY2020.

The company is one of a few in Australia — including Brisbane-based AnteoTech (ASX: ADO) — waiting on TGA approval for its diagnostic test despite lodging the application in September, ABC News reported.

Executive chairman Sam Lanyon told the publication.

We’re working with the TGA on adding some additional clinical data to the application”.

The company currently has manufacturing facilities for its rapid antigen tests in Florida and California in the United States, but not Australia.

In an investor presentation provided to the market in August, the company said it is hoping to launch its CoviDx rapid COVID-19 antigen test solution in the US, Canada and Australia in FY22 pending regulatory approvals.

This CoviDX RAT can return a result within 15 minutes of a viral swab.

The company approached Federal and State governments about local manufacture of the tests from mid-2020, but got nowhere with these discussions due to the preference for PCR tests, the ABC reported. Mr Laynson said:

For that reason, we set up our manufacturing capability out of Florida and California, which is there today, providing our range of tests into the US, European and Canadian markets at this point in time.

Lumos also has another flagship product, FebriDX, which can tell the difference between bacterial and viral infections. This product was launched in more than 100 pharmacies in the UK this week. FebriDX is also approved in Europe, Canada and Australia.

Share price snapshot

The Lumos Diagnostics share price has shed 19% in the past 52 weeks but is up 29% in the past month.

For comparison, the S&P/ASX 200 Index (ASX: XJO) has returned nearly 11% to investors in the past year.

The company commands a market capitalisation of roughly $152 million based on the current share price.

Should you invest $1,000 in Lumos right now?

Before you consider Lumos, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Lumos wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two medical researchers in white coats collaborate over a computer screen of data in a medical research laboratory
Broker Notes

Where next for the CSL share price?

CSL shares could be heading higher according to one leading broker...

Read more »

A telehealth doctor at her desk.
Healthcare Shares

Why is the Ramsay share price smashing the ASX 200 on Monday?

Ramsay shares are off to a positive start today.

Read more »

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

What’s going on with the Polynovo share price today?

The strong start has dissipated for Polynovo shares.

Read more »

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Virtus share price holds steady despite 30% earnings fall

Shareholders are staying loyal with a looming acquisition.

Read more »

a medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Earnings Results

Avita Medical share price tumbles 7% on declining Q1 revenue

The ASX healthcare share saw its net loss for the quarter increase 58% year-on-year.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance
Healthcare Shares

Own Medibank shares? Here’s what to watch over the coming months

What are the key dates for Medibank in 2022?

Read more »

A happy woman smiles as she looks at a tablet in a room with green plantlife around her. She is also wearing a green shirt representing the rising Polynovo share price
Share Gainers

Why is the Polynovo share price surging 35% in 5 days?

Polynovo shares have sprouted shoots of green in recent weeks.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Rhythm Biosciences share price lifts 5% on TGA news

The company is hoping to market and sell its cancer test kit in Australia this year.

Read more »